SARS Cov_2 Incidence of Healthy Health Workers

Baskent University

Status: Completed

Conditions: SARS COV-2 IgG Levels on Health Workers

Treatments: Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

Study type: Interventional

Funder types: Other

Identifiers

NCT04845880

KA20/449

Details and patient eligibility

About

Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.

Enrollment: 182 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy Health Workers - SARS COV-2 PCR (-)

Exclusion criteria

Health Workers - SARS COV-2 PCR (+) Pregnancy Autoimmune diseases Received immunosuppressive therapy

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

182 participants in 1 patient group

SARS Cov_2 Incidence of Healthy Health Workers

Other group

Treatment:

Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2